GlassScriptPhysician profile
Kellie Rosanbalm
NPI 1184015323
$14,624.46
in general payments reported to CMS, 2019-2025
48 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,408 · 2022: $3,791 · 2023: $3,542 · 2024: $2,453 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,035 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,034.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
| Education | $141.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,557.72 | 2021-2025 | |
| Livanova USA, INC. | $1,737.67 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,236.66 | 2021-2025 | Briviact, Nayzilam, Zilbrysq |
| Pfizer INC. | $1,103.52 | 2023-2025 | |
| Lilly USA, LLC | $841.02 | 2021-2025 | Emgality, Kisunla, Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $635.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $568.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $422.19 | 2021-2025 | |
| Axsome Therapeutics, INC. | $378.49 | 2023-2025 | Sunosi, Symbravo |
| Harmony Biosciences LLC | $280.25 | 2021-2024 | Wakix |
| Impel Pharmaceuticals INC. | $271.55 | 2023 | Trudhesa |
| Lundbeck LLC | $259.43 | 2022-2025 | Vyepti |
| Mdd US Operations, LLC | $246.66 | 2022-2024 | Gocovri, Gocovri |
| Neurelis, INC. | $242.83 | 2021-2025 | Valtoco |
| Amgen INC. | $219.98 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Rosanbalm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.